Secondary Logo

Journal Logo

Risk factors in the development of Kaposi's sarcoma

Colman, Rachel; Blackbourn, David J

doi: 10.1097/QAD.0b013e3283031a9f
CLINICAL SCIENCE: EDITORIAL COMMENTS
Free

Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK.

Received 18 March, 2008

Revised 20 March, 2008

Accepted 24 March, 2008

Correspondence to David J. Blackbourn, Cancer Research UK Institute for Cancer Studies, Vincent Drive, University of Birmingham, Edgbaston, Birmingham, B15 2TT UK. E-mail: d.j.blackbourn@bham.ac.uk

Kaposi's sarcoma is a multifocal malignancy observed in elderly Mediterranean men (so-called Classic Kaposi's sarcoma), individuals in Africa (endemic Kaposi's sarcoma) and patients with immune disorders, including those undergoing organ transplantation (iatrogenic Kaposi's sarcoma) or infected with HIV (epidemic Kaposi's sarcoma). In all of these four clinical categories of Kaposi's sarcoma, the tumour represents aberrant angiogenesis or lymphangiogenesis (i.e. formation of new blood or lymphatic vessels, respectively [1]) through proliferation of spindle-shaped endothelial cells that line these vascular structures.

Overwhelming molecular and serological evidence has now accrued to qualify Kaposi's sarcoma-associated herpesvirus (KSHV), also called human herpesvirus (HHV)-8, as the causal agent of the four clinical forms of Kaposi's sarcoma (see [2]). This virus was discovered in 1994 by Chang et al. [3], in Kaposi's sarcoma lesions where it infects the spindle cells [4] (see Fig. 1). At late stages of Kaposi's sarcoma, all spindle cells are infected with the virus [5], with low levels of lytic replication demonstrable [6]. KSHV is also associated with the pathogenesis of primary effusion lymphoma (PEL, a rare B-cell lymphoma) [7] and multicentric Castleman's disease (MCD) [8], both principally affecting AIDS patients. Its involvement in other diseases is more controversial.

Fig. 1

Fig. 1

In issue 10 of AIDS, Lanternier et al.[9] describe a cohort of 28 young, HIV-negative homosexual men with Kaposi's sarcoma. This occurrence is not a new observation as there are multiple anecdotal cases and reports of small numbers of such subjects, but the size of this cohort raises the profile of the study and enabled the authors to analyse the subjects in more detail. Does this cohort represent a fifth clinico-epidemiologic form of Kaposi's sarcoma? Unlikely, since such a significant interpretation would require compelling data that the Kaposi's sarcoma they describe differs from the four clinical forms currently recognized, for example in pathology and location of lesions. Alternatively, the cofactors predisposing these subjects to develop Kaposi's sarcoma need to be identified. Lanternier et al.[9] resolved neither requirement unequivocally, but the Kaposi's sarcoma in their cohort resembled Classic Kaposi's sarcoma: it occurred on the lower limbs and lacked visceral involvement. However, it developed 10–20 years earlier than expected for Classic Kaposi's sarcoma. Why do these younger gay men develop this Kaposi's sarcoma?

Like other oncogenic human viruses, genetic, behavioural or environmental cofactors are likely to be important in the manifestation of KSHV disease (Table 1) [10–17]. HIV is one such cofactor, at least in part because of its impact on the immune system that itself functions as an important cofactor in Kaposi's sarcoma development. In organ transplant recipients undergoing iatrogenic immunosuppressive therapy to prevent graft versus host disease, Kaposi's sarcoma can regress spontaneously upon withdrawal of the immunosuppressive therapy. Likewise, highly active antiretroviral therapy (HAART) for HIV infection restores immune function and reduces Kaposi's sarcoma incidence [18]. Given the positive correlation between KSHV replication and Kaposi's sarcoma development [18–20], and that Kaposi's sarcoma is frequently associated with immune compromise, is KSHV therefore effete, lacking in vigour? Is immune suppression a prerequisite for KSHV replication and concomitant disease manifestation?

Table 1

Table 1

Lanternier et al.'s study suggests that is not the case, as do at least two other lines of evidence. First, approximately one quarter of the KSHV genome encodes a veritable panoply of immune modulatory proteins [21]. Given that viral genomes are parsimonious, why would evolutionary pressure sustain such a diversity of immunomodulatory activities if they were not required to defend against robust immune responses capable of eliminating infected cells, not those of an immune compromised individual? Establishment of KSHV latency in vitro occurs with low efficiency and is dependent upon epigenetic factors such as modification of the chromatin structure [22]. Thus, continuous rounds of lytic infection in vivo may be required in order to recruit additional latently infected cells, which would otherwise decline as KSHV episomes are lost upon cell division. Lytic replication is also necessary for the initial establishment of infection and dissemination in the host. This dependence on lytic replication could explain the retention of the diversity of immunomodulatory activities, particularly in Kaposi's sarcoma lesions themselves, which are infiltrated with abundant leukocytes, including interferon-γ-producing cells (for further discussion, see [21]).

Second, although HIV-infected subjects with Kaposi's sarcoma typically have low CD4+ T-cell counts, a recent study [23] describes a cluster of HIV-positive, Kaposi's sarcoma-positive individuals with normal CD4+ T-cell counts. A low CD4+ T-cell count (and KSHV infection) is not therefore mandatory for the development of Kaposi's sarcoma. In some regions, such as Alexandria, Egypt, remote areas of Amazonia and Papua New Guinea and also in parts of China, KSHV prevalence is high yet the occurrence of Kaposi's sarcoma is low (reviewed in [24]). Conversely, equatorial African countries, where malaria is endemic, and certain Mediterranean countries have a higher incidence of Kaposi's sarcoma (reviewed in [25]).

These observations reinforce the cofactor theory, which brings us back to the discussion of why the subjects in the Lanternier study develop Kaposi's sarcoma. What cofactors are at work in these HIV-negative subjects? They lacked overt immune deficiency, though more subtle immune deficiencies [26] or dysfunctions cannot be excluded. Indeed, immune hyperactivity may stimulate Kaposi's sarcoma tumourigenesis as suggested by Levy and Ziegler over a decade before the discovery of KSHV [27], and this mechanism could account for Kaposi's sarcoma development when CD4+ cell counts are being restored [23]. Perhaps the Lanternier et al. [9] study subjects have a chronic underlying genetic or other causal immune dysfunction that stimulated KSHV replication and concomitant Kaposi's sarcoma development?

Equally, otherwise healthy KSHV-infected subjects may have a genetic or ethnic predisposition to developing Kaposi's sarcoma. HLA polymorphism may be important (Table 1). Many of the Lanternier subjects had travelled in countries with endemic or Classic Kaposi's sarcoma, in which the seroprevalence of KSHV is high; they might have been infected with a different, more pathogenic subtype of KSHV, but differential pathogenicity of KSHV subtypes remains controversial [28]. Other cofactors in Kaposi's sarcoma development include age, the recreational use of stimulant amyl nitrites (Table 1) and sex.

In regard to sex, KSHV prevalence is disproportionately high in homosexual men. Although KSHV is more commonly found in saliva than semen [29,30], transmission has yet to be associated with a specific homosexual practice, but does correlate with the number of lifetime sexual partners [31,32]. The seroprevalence of KSHV in heterosexual men and women is similar [33], suggesting heterosexual transmission is inefficient [34], but Kaposi's sarcoma is more common in males [2]. This sex bias is perplexing, but hormonal cofactors could be at work. In this regard, human chorionic gonadotrophin (hCG), the pregnancy hormone, has attributed anti-Kaposi's sarcoma activity in vivo with apparent physiological justification from in-vitro studies [35]. However, the presence of contaminants in commercial hCG preparations confounds these observations [36], aside from determining with certainty whether KSHV replication and/or Kaposi's sarcoma development is influenced by sex hormones.

In conclusion, the most appropriate clinico-epidemiologic classification for the subjects in the Lanternier study is ‘Classic Kaposi's sarcoma’, unless there are in the future certain risk factors (Table 1) that would place them in a separate category. KSHV causes Kaposi's sarcoma, but, if immune deficiency is not the only other risk factor associated with Kaposi's sarcoma development, what are the identities and significance of the others?

Back to Top | Article Outline

Acknowledgements

Research in D.J.B.'s laboratory is currently funded by Cancer Research UK and the Medical Research Council.

Back to Top | Article Outline

References

1. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004; 36:687–693.
2. Schulz TF. The pleiotropic effects of Kaposi's sarcoma herpesvirus. J Pathol 2006; 208:187–198.
3. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865–1869.
4. Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1995; 1:1274–1278.
5. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 1999; 96:4546–4551.
6. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997; 71:715–719.
7. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186–1191.
8. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86:1276–1280.
9. Lanternier F, Lebbé C, Schartz N, Farhi D, Marcelin AG, Kérob D, et al. Kaposi's sarcoma in HIV-negative men having sex with men. AIDS 2008; 22:1163–1168.
10. Goedert JJ, Neuland CY, Wallen WC, Greene MH, Mann DL, Murray C, et al. Amyl nitrite may alter T lymphocytes in homosexual men. Lancet 1982; 1:412–416.
11. Fung HL, Tran DC. Effects of inhalant nitrites on VEGF expression: a feasible link to Kaposi's sarcoma? J Neuroimmune Pharmacol 2006; 1:317–322.
12. Ziegler JL. Endemic Kaposi's sarcoma in Africa and local volcanic soils. Lancet 1993; 342:1348–1351.
13. Mbulaiteye SM, Biggar RJ, Pfeiffer RM, Bakaki PM, Gamache C, Owor AM, et al. Water, socioeconomic factors, and human herpesvirus 8 infection in Ugandan children and their mothers. J Acquir Immune Defic Syndr 2005; 38:474–479.
14. Coluzzi M, Calabro ML, Manno D, Chieco-Bianchi L, Schulz TF, Ascoli V. Saliva and the transmission of human herpesvirus 8: potential role of promoter-arthropod bites. J Infect Dis 2004; 190:199–200.
15. Gaya A, Esteve A, Casabona J, McCarthy JJ, Martorell J, Schulz TF, Whitby D. Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients. AIDS 2004; 18:199–204.
16. Dorak MT, Yee LJ, Tang J, Shao W, Lobashevsky ES, Jacobson LP, Kaslow RA. HLA-B, -DRB1/3/4/5, and -DQB1 gene polymorphisms in human immunodeficiency virus-related Kaposi's sarcoma. J Med Virol 2005; 76:302–310.
17. Alkharsah KR, Dedicoat M, Blasczyk R, Newton R, Schulz TF. Influence of HLA alleles on shedding of Kaposi sarcoma-associated herpesvirus in saliva in an African population. J Infect Dis 2007; 195:809–816.
18. Martro E, Esteve A, Schulz TF, Sheldon J, Gambus G, Munoz R, et al. Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study. Int J Cancer 2007; 120:1129–1135.
19. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346:799–802.
20. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063–1070.
21. Rezaee SAR, Cunningham C, Davison AJ, Blackbourn DJ. KSHV immune modulation: an overview. J Gen Virol 2006; 87:1781–1804.
22. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 2004; 113:124–136.
23. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357:1352–1353.
24. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 2003; 17:1717–1730.
25. Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic kaposi sarcoma: epidemiology and risk factors. Cancer 2000; 88:500–517.
26. Guihot A, Dupin N, Marcelin AG, Gorin I, Bedin AS, Bossi P, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194:1078–1088.
27. Levy JA, Ziegler JL. Acquired immunodeficiency syndrome is an opportunistic infection and Kaposi's sarcoma results from secondary immune stimulation. Lancet 1983; 2:78–81.
28. Zong J-C, Arav-Boger R, Alcendor DJ, Hayward GS. Reflections on the interpretation of heterogeneity and strain differences based on very limited PCR sequence data from Kaposi's sarcoma-associated herpesvirus genomes. J Clin Virol 2007; 40:1–8.
29. Blackbourn DJ, Lennette ET, Ambroziak J, Mourich DV, Levy JA. Human herpesvirus 8 detection in nasal secretions and saliva. J Infect Dis 1998; 177:213–216.
30. Blackbourn DJ, Levy JA. Human herpesvirus 8 in semen and prostate. AIDS 1997; 11:249–250.
31. Blackbourn DJ, Osmond D, Levy JA, Lennette ET. Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. J Infect Dis 1999; 179:237–239.
32. Martin JN. Moving toward clarity on 2 fronts in the epidemiology of Kaposi sarcoma-associated herpesvirus infection. J Infect Dis 2007; 196:173–175.
33. Engels EA, Atkinson JO, Graubard BI, McQuillan GM, Gamache C, Mbisa G, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007; 196:199–207.
34. Malope BI, MacPhail P, Mbisa G, MacPhail C, Stein L, Ratshikhopha EM, et al. No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. AIDS 2008; 22:519–526.
35. Pfeffer U, Bisacchi D, Morini M, Benelli R, Minghelli S, Vacca A, et al. Human chorionic gonadotropin inhibits Kaposi's sarcoma associated angiogenesis, matrix metalloprotease activity, and tumor growth. Endocrinology 2002; 143:3114–3121.
36. Simonart T, Van Vooren JP, Meuris S. Treatment of Kaposi's sarcoma with human chorionic gonadotropin. Dermatology 2002; 204:330–333.
© 2008 Lippincott Williams & Wilkins, Inc.